Liav Abraham Recent News
It's Not Over For Teva Just Yet After J-Code Rejection, Citi Says
Is Allergan Worth Over $300 Without Pfizer?
2 Pharma Stocks To Hide In While Drug Pricing Fears Play Out
Citi Asks: Is A Mylan-Perrigo Merger Smart?
And The Winner From The Mylan-Perrigo Merger Is... Teva?
Does Teva Pharmaceutical's New Executive Hint At A Coming M&A Deal?
Citigroup Says Actavis Is Now Worth $360 Per Share (And It's A Buy)
Citigroup Ponders How Results From Namenda Survey Might Affect Actavis
Citigroup Offers Thoughts On Zoetis Ahead Of Investor Day
Citi Raises Price Target On Actavis
UPDATE: Citigroup Initiates Coverage On DBV Technologies As Stock Is Not Fully Appreciated
Analyst: Bill Ackman's Zoetis Move Casts Doubt On Allergan Bid
UPDATE: Citigroup Reiterates On Zoetis Following Pershing Confirmation
Activis Shares Languish Post-Forest Deal
Analysts See Allergan Bid Of Over $180, Possibility of 'Hostile' Bid
Citigroup Slaps $70 Price Target on Teva, Highest on Street
Teva Offers Most Attractive Risk-Reward Profile, Citigroup Says
UPDATE: Allergan Upgraded by Citigroup on Strong Fundamentals
UPDATE: Citigroup Reiterates on Endo Health Solutions on Potential of Paladin Acquisition
UPDATE: Citigroup Initiates Coverage on Actavis PLC as Stock is Firing on All Cylinders
UPDATE: Citigroup Initiates Coverage on Teva Pharmaceutical Industries Ltd. on Attractive Risk-Reward Profile